Advances in immunotherapy for hepatocellular carcinoma

Published on Apr 13, 2021in Nature Reviews Gastroenterology & Hepatology29.848
· DOI :10.1038/S41575-021-00438-0
Bruno Sangro77
Estimated H-index: 77
(University of Navarra),
Pablo Sarobe38
Estimated H-index: 38
(University of Navarra)
+ 1 AuthorsIgnacio Melero81
Estimated H-index: 81
(University of Navarra)
Sources
Abstract
Hepatocellular carcinoma (HCC) is a prevalent disease with a progression that is modulated by the immune system. Systemic therapy is used in the advanced stage and until 2017 consisted only of antiangiogenic tyrosine kinase inhibitors (TKIs). Immunotherapy with checkpoint inhibitors has shown strong anti-tumour activity in a subset of patients and the combination of the anti-PDL1 antibody atezolizumab and the VEGF-neutralizing antibody bevacizumab has or will soon become the standard of care as a first-line therapy for HCC, whereas the anti-PD1 agents nivolumab and pembrolizumab are used after TKIs in several regions. Other immune strategies such as adoptive T-cell transfer, vaccination or virotherapy have not yet demonstrated consistent clinical activity. Major unmet challenges in HCC checkpoint immunotherapy are the discovery and validation of predictive biomarkers, advancing treatment to earlier stages of the disease, applying the treatment to patients with liver dysfunction and the discovery of more effective combinatorial or sequential approaches. Combinations with other systemic or local treatments are perceived as the most promising opportunities in HCC and some are already under evaluation in large-scale clinical trials. This Review provides up-to-date information on the best use of currently available immunotherapies in HCC and the therapeutic strategies under development.
📖 Papers frequently viewed together
3 Authors (Lin Liu, ..., Yu Zhang)
2 Citations
12 Citations
76 Citations
References211
Newest
#1Jordi RimolaH-Index: 43
#2Leonardo G. Da Fonseca (University of Barcelona)H-Index: 5
Last. Maria ReigH-Index: 33
view all 19 authors...
Abstract Background and Aims Immune-checkpoint inhibitors are effective in many advanced tumors. However, there is scarce information regarding the radiological response to these agents in hepatocellular carcinoma outside clinical trials. We aimed to describe the radiological response in a retrospective cohort of hepatocellular carcinoma patients treated with nivolumab and to analyze the radiological evolution according to tumor response at first posttreatment radiological assessment. Methods We...
6 CitationsSource
267Background: Atezo + bev has been approved globally for pts with unresectable HCC who have not received prior systemic therapy, based on results from IMbrave150 (NCT03434379). At a median of 8.6 ...
60 CitationsSource
#1Josep M. LlovetH-Index: 120
#2Robin Kate KelleyH-Index: 36
Last. Richard S. FinnH-Index: 80
view all 10 authors...
Liver cancer remains a global health challenge, with an estimated incidence of >1 million cases by 2025. Hepatocellular carcinoma (HCC) is the most common form of liver cancer and accounts for ~90% of cases. Infection by hepatitis B virus and hepatitis C virus are the main risk factors for HCC development, although non-alcoholic steatohepatitis associated with metabolic syndrome or diabetes mellitus is becoming a more frequent risk factor in the West. Moreover, non-alcoholic steatohepatitis-asso...
1,794 Citations
#1John D. Gordan (UCSF: University of California, San Francisco)H-Index: 28
#2Erin B. Kennedy (American Society of Clinical Oncology)H-Index: 18
Last. Michal G. Rose (Yale Cancer Center)H-Index: 5
view all 27 authors...
PURPOSETo develop an evidence-based clinical practice guideline to assist in clinical decision making for patients with advanced hepatocellular carcinoma (HCC).METHODSASCO convened an Expert Panel ...
43 CitationsSource
#1Thomas Yau (HKU: University of Hong Kong)H-Index: 43
#2Yoon-Koo Kang (Asan Medical Center)H-Index: 77
Last. Chiun Hsu (NTU: National Taiwan University)H-Index: 44
view all 21 authors...
Importance Most patients with hepatocellular carcinoma (HCC) are diagnosed with advanced disease not eligible for potentially curative therapies; therefore, new treatment options are needed. Combining nivolumab with ipilimumab may improve clinical outcomes compared with nivolumab monotherapy. Objective To assess efficacy and safety of nivolumab plus ipilimumab in patients with advanced HCC who were previously treated with sorafenib. Design, setting, and participants CheckMate 040 is a multicente...
144 CitationsSource
12 CitationsSource
#1Ivan Marquez-RodasH-Index: 26
#3Maria E. Rodriguez-Ruiz (University of Navarra)H-Index: 27
Last. Ignacio Melero (University of Navarra)H-Index: 81
view all 27 authors...
Intratumoral therapies, especially Toll-like receptor agonists, can trigger both the innate and adaptive immune systems. BO-112 is a nanoplexed form of polyinosinic:polycytidylic acid (poly I:C) that induces local and systemic immunotherapeutic effects in mouse models. In a multicenter phase 1 clinical trial, repeated intratumoral administrations of BO-112 induced an increase in tumor cell necrosis and apoptosis, as well as augmented immune reactivity according to gene expression profiling. The ...
12 CitationsSource
Abstract Background & Aims Nivolumab, a programmed death (PD)-1 (PD-1) inhibitor, demonstrated durable responses, manageable safety, and increased survival in patients with advanced hepatocellular carcinoma (HCC). Our retrospective analysis studied the immunobiology and potential associations between biomarkers and nivolumab outcomes in HCC. Methods Fresh and archival tumour samples from dose-escalation and -expansion phases of CheckMate 040 were analysed by immunohistochemistry and RNA sequenci...
45 CitationsSource
17 CitationsSource
#1Thoetchai Peeraphatdit (U of C: University of Chicago)H-Index: 8
#2Jennifer Wang (U of C: University of Chicago)H-Index: 3
Last. Michael Charlton (U of C: University of Chicago)H-Index: 84
view all 6 authors...
Immune checkpoint inhibitors (ICIs) are monoclonal antibodies targeting immune checkpoint molecules. ICIs are a novel immunotherapy for the treatment of many advanced malignancies. The advent of ICIs has been a major breakthrough in the field of oncology, a fact recognized by the 2018 Nobel Prize in Physiology or Medicine being awarded for the discovery. The Food and Drug Administration (FDA) approved the first ICI, ipilimumab, in 2011 for the treatment of metastatic melanoma. Seven ICIs are now...
32 CitationsSource
Cited By23
Newest
#1Ha Zhu ('SMMU': Second Military Medical University)
#2Mingyan Huang ('SMMU': Second Military Medical University)
Last. Qiuyan Liu ('SMMU': Second Military Medical University)
view all 0 authors...
Neurotrophic factors and their receptors have been identified to promote tumor progression. GFRα1, the receptor for glial cell line-derived neurotrophic factor (GDNF), has been demonstrated to be predominantly expressed in adult liver tissue. Our preliminary data showed that GFRα1 is significantly downregulated in hepatocellular carcinoma (HCC) tissue, compared to the matched non-neoplastic tissue. However, the role of GFRα1 in HCC progression remains unknown. Here we found that the expression o...
Source
Source
Source
#1Soha A Hassan (Suez University)H-Index: 2
#2Amira A. H. Ali (HHU: University of Düsseldorf)H-Index: 4
Last. Charlotte von Gall (HHU: University of Düsseldorf)H-Index: 10
view all 7 authors...
This study investigates whether a chronotherapeutic treatment of hepatocellular carcinoma (HCC) may improve treatment efficacy and mitigate side effects on non-tumoral liver (NTL). HCC was induced in Per2::luc mice which were irradiated at four time points of the day. Proliferation and DNA-double strand breaks were analyzed in irradiated and nonirradiated animals by detection of Ki67 and γ-H2AX. Prior to whole animal experiments, organotypic slice cultures were investigated to determine the dosa...
Source
#1Yen-Yang ChenH-Index: 13
#2Chao-Long ChenH-Index: 59
Last. Yen-Hao ChenH-Index: 8
view all 7 authors...
Tumor recurrence is the most common cause of death in hepatocellular carcinoma (HCC) patients who received liver transplantation (LT). Recently, lenvatinib was approved for the systemic treatment of unresectable HCC patients; however, the role of lenvatinib in HCC patients after LT remains unclear. There were 56 patients with recurrent HCC after LT from 2008 to 2018 in our institute, and 10 patients who received lenvatinib were identified. Additionally, to understand the difference in the clinic...
Source
#1Haichuan Wang (Sichuan University)H-Index: 9
#2Xin Chen (UCSF: University of California, San Francisco)H-Index: 62
Last. Diego F. Calvisi (University of Regensburg)H-Index: 18
view all 3 authors...
INTRODUCTION : Hepatocellular carcinoma (HCC) is a malignant liver tumor characterized by high molecular heterogeneity, which has hampered the development of effective targeted therapies severely. Recent experimental data have unraveled novel promising targets for HCC treatment. AREAS COVERED : Eligible articles were retrieved from PubMed and Web of Science databases up to July 2021. This review summarizes the established targeted therapies for advanced HCC, focusing on the strategies to overcom...
Source
Source
#1Zhen Lin (ZJU: Zhejiang University)
#2Yi-Zhao Xie (Fudan University Shanghai Medical College)
Last. Guang-Liang Chen (Fudan University Shanghai Medical College)
view all 6 authors...
BACKGROUND Xanthine dehydrogenase (XDH) is a critical enzyme involved in the oxidative metabolism of purines, pterin and aldehydes and a central component of the innate immune system. However, the prognostic value of XDH in predicting tumor-infiltrating lymphocyte abundance, the immune response, and survival in different cancers, including hepatocellular carcinoma (HCC), is still unclear. METHODS XDH expression was analyzed in multiple databases, including Oncomine, the Tumor Immune Estimation R...
Source
#1Barbara Mandriani (University of Bari)H-Index: 10
#2Eleonora Pelle (University of Bari)H-Index: 5
Last. Camillo Porta (University of Bari)H-Index: 68
view all 8 authors...
Multiple systemic treatments are currently available for advanced cancers of the digestive tract, but none of them is curative. Adoptive T-cell immunotherapy refers to the extraction, modification and re-infusion of autologous or allogenic T lymphocytes for therapeutic purposes. A number of clinical trials have investigated either non-engineered T cells (i.e., lymphokine-activated killer cells, cytokine induced killer cells, or tumor-infiltrating lymphocytes) or engineered T cells (T cell recept...
Source
Hepatocellular carcinoma (HCC) is a common cause of cancer-related deaths worldwide. Unlike other types of cancer, HCC can be treated with locoregional treatments (LRTs) such as radiofrequency ablation (RFA) or transarterial chemoembolization (TACE). However, recurrences following LRTs are common, and strategies to improve long-term outcomes need to be developed. The exhaustion of anti-tumor immunity in HCC has been well established in many reports and the immunomodulatory effects of LRTs (enhan...
Source